A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
Rahul Raj Aggarwal
No relevant relationships to disclose
Vivian K. Weinberg
No relevant relationships to disclose
Charles J. Ryan
No relevant relationships to disclose
Andrea Harzstark
No relevant relationships to disclose
Alan H. Bryce
No relevant relationships to disclose
Christina Louise Derleth
No relevant relationships to disclose
Kimberly Lowe
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose